Abstract 2311P
Background
Interleukin-2 receptor (IL2R) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) are key immunotherapeutic targets in cancer treatment. GI-101, a novel bispecific Fc fusion protein, targets both CTLA4 and IL2Rβγ, offering potential for improved patient outcomes. This study developed a mathematical model linking GI-101 pharmacokinetics (PK), absolute lymphocyte count (ALC) dynamics, and progression-free survival (PFS) to optimize the biological dose for maximal therapeutic benefit.
Methods
Preclinical monkey (n=74) and phase 1/2 human (n=31) data of GI-101 were used for model development. The dataset was randomly split into training and test datasets at a ratio of 7 to 3, and the final model was validated using the test dataset. Data from a phase 1/2 clinical trial were analyzed using a random survival forest algorithm to assess the effect of immune cell dynamics on PFS. Potential dose-response correlations were assessed for Grade 3 or 4 treatment-related adverse events (TrAE) and immune-related adverse events (irAE) using logistic regression. Stochastic simulations determined the optimal biological dose (OBD) to achieve the target peak ALC.
Results
A pharmacodynamics-mediated drug disposition (PDMDD) model adequately described drug pharmacokinetics, captured changes of cell count across all lymphocyte subsets, and demonstrated strong performance in the test dataset. Random survival forest analysis of the GI-101 clinical data revealed that peak total lymphocyte (p=0.00191) and CD8+ T cell (p=0.00515) counts significantly predicted PFS. There was no significant dose-response correlation for TrAE (p=0.66) and irAE (p=0.92). Simulations suggested an OBD of 0.3 mg/kg every three weeks, achieving target peak total lymphocyte and CD8+ T cell counts of 2,000 cells/μL and 350 cells/μL, respectively.
Conclusions
Our findings underscore the value of translational mathematical modeling for informing optimal dosing strategies in novel immunotherapies targeting IL2βγR and CTLA4. The identified OBD merits further investigation in clinical trials to validate its potential for enhancing patient outcomes.
Clinical trial identification
NCT04977453
Editorial acknowledgement
Legal entity responsible for the study
GI Innovation, Inc.
Funding
GI Innovation, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2283P - Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Presenter: Benjamin Schoeps
Session: Poster session 08
2284P - Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
Presenter: Andreas Ackermann
Session: Poster session 08
2285P - Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls
Presenter: Pedro Cruz
Session: Poster session 08
2286P - COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer
Presenter: Ha Mo Linh Le
Session: Poster session 08
2288P - Recolony-treating solid tumors with a bacteria-based approach
Presenter: Egle Katkeviciute
Session: Poster session 08
2289P - Determining anti-cancer efficacy of a reversible LSD1 inhibitor, EXS74539, in primary AML tissues with limited thrombocytopenic effects
Presenter: Christophe Boudesco
Session: Poster session 08
2291P - WU-NK-101, best in class memory-NK cell, has key features vital for adoptive cell therapy (ACT) in solid tumors (ST)
Presenter: John Muth
Session: Poster session 08
2292P - Prevalence of druggable EGFR genomic alterations in solid tumours other than lung cancer
Presenter: Tomohiro Kondo
Session: Poster session 08
2293P - Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers
Presenter: Carlotta Catozzi
Session: Poster session 08